Published in Arch Dis Child on February 01, 1985
Profound Vitamin D Deficiency in a Diverse Group of Women during Pregnancy Living in a Sun-Rich Environment at Latitude 32°N. Int J Endocrinol (2010) 1.13
Calcium and vitamin D status of pregnant teenagers in Maiduguri, Nigeria. J Natl Med Assoc (1997) 0.86
Mineral transport across the placenta. Arch Dis Child (1992) 0.79
The effect of cigarette smoke exposure on vitamin D level and biochemical parameters of mothers and neonates. J Diabetes Metab Disord (2013) 0.77
Cross-sectional study of serum parathyroid hormone level in high-risk pregnancies as compared to nonpregnant control. Indian J Endocrinol Metab (2016) 0.75
Parathormone and perinatal calcium homeostasis. Pediatr Res (1979) 1.87
Physiologic hyperparathyroidism in pregnancy. J Clin Endocrinol Metab (1972) 1.70
Bovine parathyroid hormone: minimum chain length of synthetic peptide required for biological activity. Endocrinology (1973) 1.65
Calcium metabolism in normal human pregnancy. J Clin Endocrinol Metab (1971) 1.55
Calcium metabolism in newborn infants. The interrelationship of parathyroid function and calcium, magnesium, and phosphorus metabolism in normal, "sick," and hypocalcemic newborns. J Clin Invest (1974) 1.52
Studies of circulating parathyroid hormone in man using a homologous amino-terminal specific immunoradiometric assay. Clin Endocrinol (Oxf) (1980) 1.29
Calcium, magnesium, phosphorus, and parathyroid hormone interrelationships in pregnancy and newborn infants. Obstet Gynecol (1977) 1.22
Calcium metabolism in pregnancy: a review. Am J Obstet Gynecol (1975) 1.20
Serial measurements of serum calcium, magnesium, parathyroid hormone, calcitonin, and 25-hydroxy-vitamin D in premature and term infants during the first week of life. Pediatr Res (1977) 1.19
Vitamin D homeostasis in the perinatal period: 1,25-dihydroxyvitamin D in maternal, cord, and neonatal blood. N Engl J Med (1980) 1.14
A sensitive bioassay of parathyroid hormone in plasma. Clin Endocrinol (Oxf) (1978) 1.07
Complete amino acid sequence of human parathyroid hormone. Biochemistry (1978) 1.06
Neonatal parathyroid function: role of gestational age and postnatal age. J Pediatr (1973) 1.06
Calcitonin and parathyroid hormone--relation to early neonatal hypocalcemia in infants of diabetic mothers. Biol Neonate (1974) 0.97
Perinatal vitamin D metabolism. IV. Maternal and cord serum 24,25-dihydroxyvitamin D concentrations. J Clin Endocrinol Metab (1978) 0.97
Preliminary studies with the sensitive cytochemical assay for parathyroid hormone. Clin Endocrinol (Oxf) (1978) 0.97
Perinatal parathyroid hormone, vitamin D metabolites, and calcitonin in man. Am J Physiol (1980) 0.97
Serum calcium concentrations in human pregnancy. Am J Obstet Gynecol (1977) 0.97
Cytochemical bioassay of parathyroid hormone: characteristics of the assay and analysis of circulating hormonal forms. J Clin Invest (1980) 0.96
FUNCTIONAL CAPACITY OF FETAL PARATHYROID GLANDS WITH REFERENCE TO THEIR CLINICAL USE AS HOMOGRAFTS. Ann N Y Acad Sci (1964) 0.95
Placental transfer of fluoride and calcium. Am J Obstet Gynecol (1970) 0.90
Fetal calcitropic hormones and neonatal calcium homeostasis. Pediatrics (1980) 0.90
Total, protein-bound, and ultrafilterable calcium in maternal and fetal plasmas. Am J Physiol (1967) 0.88
The measurement of the transfer of calcium and phosphorus from foetus to dam in the sheep using a whole body counter. Res Vet Sci (1972) 0.85
Maternal-fetal calcium relationships in man. Q J Exp Physiol Cogn Med Sci (1972) 0.85
The cytochemical bioassay of parathyroid hormone: further experience. J Immunoassay (1983) 0.85
Serum concentrations of parathyroid hormone in infants, children, and adolescents. J Pediatr (1974) 0.85
Serum ionic calcium levels during pregnancy. J Obstet Gynaecol Br Commonw (1972) 0.85
Maternal and fetal parathyroid hormone responsiveness in pregnant primates. J Clin Endocrinol Metab (1980) 0.83
A radioimmunoassay for parathyroid hormone in man. II. Measurement of parathyroid hormone concentrations in human plasma by means of a radioimmunoassay for bovine hormone. Acta Endocrinol (Copenh) (1970) 0.82
Immunocytological evidence for parathyroid hormone in human fetal parathyroid glands. J Clin Endocrinol Metab (1981) 0.81
Clearance of exogenous parathyroid hormone in normal and uraemic man. Clin Endocrinol (Oxf) (1977) 0.80
Maternal and cord blood at delivery. IV. Glucose, sodium, potassium, calcium and chloride. Biol Neonat (1965) 0.80
A carboxy-terminal specific assay for human parathyroid hormone. Clin Endocrinol (Oxf) (1981) 0.79
Parathyroid function in infants of diabetic mothers. J Pediatr (1975) 0.78
The rôle of parathyroid hormone in the aetiology of neonatal hypocalcaemia. Postgrad Med J (1975) 0.77
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. Lancet (1978) 3.59
Vitamin-D deficiency among Asian immigrants to Britain. Lancet (1973) 3.26
Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11
Studies of vitamin D deficiency in man. Q J Med (1975) 2.94
Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int (2006) 2.79
A competitive protein-binding assay for 25-hydroxycholecalciferol and 25-hydroxyergocalciferol in serum. Clin Chim Acta (1974) 2.62
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res (2003) 2.50
Presentation of vitamin D deficiency. Arch Dis Child (2004) 2.50
A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol (2000) 2.47
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA (1997) 2.46
Parathyroid venous sampling: anatomic considerations and results in 95 patients with primary hyperparathyroidism. Br J Radiol (1980) 2.29
The time course of a hypercalcaemic crisis in acute primary hyperparathyroidism. Lancet (1984) 2.21
Immunoradiometric assay of parathyroid hormone. J Endocrinol (1971) 2.19
British Paediatric and Adolescent Bone Group's position statement on vitamin D deficiency. BMJ (2012) 2.05
Hypocalcaemia and vitamin D deficiency: an important, but preventable, cause of life-threatening infant heart failure. Heart (2007) 2.04
Production of parathyroid hormone by nonparthyroid tumors. J Clin Endocrinol Metab (1967) 2.00
Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia. Lancet (1983) 2.00
Isolation and chemical properties of porcine parathyroid hormone. Biochemistry (1971) 1.92
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Quantitative heel ultrasound in a population-based study in Italy and its relationship with fracture history: the ESOPO study. Osteoporos Int (2005) 1.80
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res (2000) 1.80
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care (2001) 1.74
1, 25-dihydroxycholecalciferol in the pathogenesis of the hypercalcaemia of sarcoidosis. Lancet (1979) 1.71
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet (1997) 1.64
Corticotrophin-secreting carcinomas. Q J Med (1966) 1.64
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int (2006) 1.54
Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med (1989) 1.52
Prevention of vitamin-D deficiency in Asians. Lancet (1976) 1.45
Bone loss in response to long-term glucocorticoid therapy. Bone Miner (1990) 1.44
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab (1999) 1.43
Clinical and subclinical vitamin D deficiency in Bradford children. Arch Dis Child (1976) 1.41
Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) (2001) 1.40
Vitamin D status in different subgroups of British Asians. Br Med J (1976) 1.40
The amino-acid sequence of the amino-terminal 37 residues of human parathyroid hormone. Proc Natl Acad Sci U S A (1974) 1.37
Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int (2003) 1.36
Studies of circulating parathyroid hormone in man using a homologous amino-terminal specific immunoradiometric assay. Clin Endocrinol (Oxf) (1980) 1.29
Secretion of parathyroid hormone in primary hyperparathyroidism. Clin Endocrinol (Oxf) (1972) 1.27
Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int (2012) 1.25
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res (2002) 1.22
A radioimmunoassay for 1,25-dihydroxycholecalciferol. Clin Sci Mol Med (1978) 1.22
Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. Immunology (1987) 1.20
Regulation of human tonsillar T-cell proliferation by the active metabolite of vitamin D3. Immunology (1986) 1.19
Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet (1995) 1.17
The amino acid sequence of porcine parathyroid hormone. Biochemistry (1974) 1.16
Hyperparathyroidism in chronic renal failure and dialysis osteodystrophy. Q J Med (1970) 1.15
Structure-function studies in parathyroid hormone. Proc R Soc Med (1971) 1.15
Preoperative localisation of parathyroid tumours. Lancet (1971) 1.14
Radioimmunoassay of 1,25-dihydroxy vitamin D2: studies on the metabolism of vitamin D2 in man. Clin Endocrinol (Oxf) (1983) 1.13
Studies of the hypercalcaemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3. Q J Med (1984) 1.13
Immunological reactivity of purified human parathyroid hormone. Proc Natl Acad Sci U S A (1969) 1.11
Isolation of human parathyroid hormone. Endocrinology (1971) 1.09
End-organ resistance to 1,25-dihydroxycholecalciferol. Lancet (1980) 1.09
Reversible resistance to the renal action of parathyroid hormone in human vitamin D deficiency. Clin Sci (Lond) (1982) 1.09
Hypomagnesaemia: studies of parathyroid hormone secretion and function. Clin Endocrinol (Oxf) (1984) 1.08
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis (2004) 1.06
Vitamin D-dependent rickets type II: extreme end organ resistance to 1,25-dihydroxy vitamin D3 in a patient without alopecia. Eur J Pediatr (1986) 1.06
Measurement of 1,25-dihydroxycholecalciferol in man by radioimmunoassay. Clin Endocrinol (Oxf) (1979) 1.05
Changes in insulin sensitivity in response to different modalities of exercise: a review of the evidence. Diabetes Metab Res Rev (2014) 1.03
Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporos Int (2007) 1.03
Structure, synthesis, and mechanism of action of parathyroid hormone. Recent Prog Horm Res (1972) 1.03
Prevalence and correlates of vertebral fractures in adults with cystic fibrosis. Bone (2004) 1.02
Mapping the gene causing X-linked recessive idiopathic hypoparathyroidism to Xq26-Xq27 by linkage studies. J Clin Invest (1990) 1.02
[Incidence and socioeconomic burden of hip fractures in Italy]. Reumatismo (2005) 1.02
Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol (1985) 1.02
Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis (2007) 1.01
Two mutations in the hormone binding domain of the vitamin D receptor cause tissue resistance to 1,25 dihydroxyvitamin D3. J Clin Invest (1993) 1.00
Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int (2013) 1.00
Mutations in the vitamin D receptor gene in three kindreds associated with hereditary vitamin D resistant rickets. J Clin Endocrinol Metab (1997) 1.00
Relation between adiponectin and bone mineral density in elderly post-menopausal women: role of body composition, leptin, insulin resistance, and dehydroepiandrosterone sulfate. J Endocrinol Invest (2008) 1.00
Density gradient centrifugation of human and bovine parathyroid hormone. Endocrinology (1967) 0.99
Construction of a high-resolution linkage map for Xp22.1-p22.2 and refinement of the genetic localization of the Coffin-Lowry syndrome gene. Genomics (1994) 0.99
Intermittent hypercalcaemia and vitamin D sensitivity in Hodgkin's disease. Postgrad Med J (1990) 0.99
Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost (1995) 0.98
Studies of hypoparathyroidism and pseudohypoparathyroidism. Q J Med (1978) 0.97
The gene for X-linked hypophosphataemic rickets maps to a 200-300kb region in Xp22.1, and is located on a single YAC containing a putative vitamin D response element (VDRE). Hum Genet (1996) 0.96
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int (2001) 0.96
Tissue resistance to 1,25-dihydroxyvitamin D without a mutation of the vitamin D receptor gene. Clin Endocrinol (Oxf) (1993) 0.95
Age-related cortical bone loss at the metacarpal. Calcif Tissue Int (1997) 0.95
Relationship among VDR (BsmI and FokI), COLIA1, and CTR polymorphisms with bone mass, bone turnover markers, and sex hormones in men. Calcif Tissue Int (2002) 0.95
An investigation of the biological activity of parathyroid hormone in pseudohypoparathyroidism: comparison with vitamin D deficiency. Clin Endocrinol (Oxf) (1984) 0.94
Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res (1994) 0.94
Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD. Bone Miner (1986) 0.94
Association of CTR and COLIA1 alleles with BMD values in peri- and postmenopausal women. Calcif Tissue Int (2000) 0.93
Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res (2001) 0.93
Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calcif Tissue Int (1986) 0.92
Familial benign hypercalcaemia. Study of a large family. Q J Med (1983) 0.91
Treatment of hypercalcaemia with calcitonin. Lancet (1971) 0.91